	FORM 4	UNITED STATES SECURITIES AND EXCHANGE COMMISSION		
		Washington, D.C. 20549	OMB APPROVA	
(m)	Check this box if no longer subject to Section 16. Form 4 or Form 5	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP	OMB Number: Estimated average burg	3235 den
	obligations may continue. See Instruction 1(b).	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934	hours per response:	

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

3235-0287

0.5

					-	tion 30(n) of the Ir				940								
1. Name and Address of Reporting Person*						2. Issuer Name and Ticker or Trading Symbol ANGIODYNAMICS INC [ ANGO ]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
Nighan Warren JR								L	. 1			Director		10% C				
(Lest)	(Fire	.4)		3. Date of Earliest Transaction (Month/Day/Year)							ve title	Other below	(specify )					
(Last)	(Firs	,	0//1//2	07/17/2024						SVP Quality and Regulatory								
ANGIODY	NAMICS,	INC.			<u> </u>						_			0				
14 PLAZA DRIVE					4. If Am	4. If Amendment, Date of Original Filed (Month/Day/Year)						6. Individual or Joint/Group Filing (Check Applicable Line)						
					-						1	Form filed	by One F	Reporting Pers	on			
(Street) LATHAM	NY									Form filed Person	by More	than One Repo	orting					
(City)	(Sta	te)	Rule	Rule 10b5-1(c) Transaction Indication														
			Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.															
		Та	ble I - Nor	n-Deri	vative S	ecurities Acq	uired,	Disp	oosed of, o	or Bene	ficially	Owned						
1. Title of Security (Instr. 3) Date (Month/					saction n/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transa Code ( 8)		4. Securities Disposed Of			5. Amount of Securities Beneficially Owned Following Reported		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership			
					Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)			(Instr. 4)					
Common Sto	ock			7/2024		A		18,733(1)	A	\$0	42,26	51	D					
						curities Acqu Is, warrants,			•			wned						
1. Title of 2	le of 2. 3. Transaction 3A. Deemed 4. 5. Number 6. Date Exercisable and 7. Title and							Amount	8. Price of 9	. Number	of 10.	11. Nature						

Derivative Security (Instr. 3)	Conversion or Exercise Price of Derivative Security	Date (Month/Day/Year)	Execution Date, if any (Month/Day/Year)	Transaction Code (Instr. 8)		of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		Expiration Date (Month/Day/Year)		of Securities Underlying Derivative Security (Instr. 3 and 4)		Derivative Security (Instr. 5)	derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Performance Right	(2)	07/17/2024		Α		23,952		(2)	(2)	Common Stock	23,952	\$ <mark>0</mark>	23,952	D	
Non- Qualified Stock Option (right to buy)	\$7.4	07/17/2024		А		23,507		07/17/2025 <sup>(3)</sup>	07/17/2034	Common Stock	23,507	\$ <b>0</b>	23,507	D	

## Explanation of Responses:

1. The acquisition of 18,733 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 18,733 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 17, 2025, such that 25% of the restricted stock units will vest on each of July 17, 2025, 2026, 2027 and 2028. 2. Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

3. These stock options vest in four equal annual installments beginning on July 17, 2025, such that 25% of the options will vest on each of July 17, 2025, 2026, 2027 and 2028.

## Remarks:

SEC Form 4

Exhibit List: Exhibit 24.1 - Power of Attorney

<u>/s/ Stephen A. Trowbridge,</u> <u>Attorney in Fact</u>	<u>07/19/2024</u>
** Signature of Reporting Person	Date

\*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

## POWER OF ATTORNEY

Know all by these presents, that the undersigned hereby constitutes and appoints Stephen A. Trowbridge, and with full power of substitution, the undersigned's true and lawful attorney-in-fact to:

- (1) prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to the U.S. Securities and Exchange Commission (the "SEC") a Form ID, including amendments thereto, and any other documents necessary or appropriate to obtain codes and passwords enabling the undersigned to make electronic filings with the SEC of reports required by Section 16(a) of the Securities Exchange Act of 1934 or any rule or regulation of the SEC;
- (2) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer and/or director of AngioDynamics, Inc. (the "Company"), Forms 3, 4, and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder;
- (3) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4, or 5, complete and execute any amendment or amendments thereto, and timely file such form with the SEC and any stock exchange or similar authority; and
- (4) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorney-in-fact, in serving in such capacity at the request of the undersigned, is not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorney-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 19th day of July, 2024.

/s/ Warren Nighan Signature

Warren Nighan Print Name